[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].. Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)

Archive ouverte

Rousset-Jablonski, Christine | Selle, Frédéric | Adda-Herzog, Elodie | Planchamp, François | Selleret, Lise | Pomel, Christophe | Chabbert-Buffet, Nathalie | Darai, Emile | Pautier, Patricia | Trémollières, Florence | Guyon, Frédéric | Rouzier, Roman | Laurence, Valérie | Chopin, Nicolas | Faure-Conter, Cécile | Bentivegna, Enrica | Vacher-Lavenu, Marie-Cécile | Lhomme, Catherine | Floquet, Anne | Treilleux, Isabelle | Lecuru, Fabrice | Gouy, Sébastien | Kalbacher, Elsa | Genestie, Catherine | de La Motte Rouge, Thibault | Ferron, Gwenaël | Devouassoux-Shisheboran, Mojgan | Kurtz, Jean-Emmanuel | Namer, Moïse | Joly, Florence | Pujade-Lauraine, Eric | Grynberg, Michael | Querleu, Denis | Morice, Philippe | Gompel, Anne | Ray-Coquard, Isabelle

Edité par CCSD ; Elsevier -

National audience. Introduction - Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. Methods - A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. Results - Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. Discussion - In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

Suggestions

Du même auteur

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study

Archive ouverte | Hanvic, Brunhilde | CCSD

International audience

Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa »

Archive ouverte | Lavoue, Vincent | CCSD

National audience

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

Archive ouverte | Rouzier, Roman | CCSD

International audience. To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (...

Chargement des enrichissements...